2026 Assessment Of The Nuvisertib Market: Sales Forecasts, Clinical Differentiation, Competitive Threats, And Commercial Opportunities Through 2034
Dublin, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The "Nuvisertib Sales Forecast, and Market Size Analysis - 2034" has been added to ResearchAndMarkets.com's offering.
Nuvisertib (TP-3654) is an investigational, orally administered, highly selective PIM1 kinase inhibitor being developed by Sumitomo Pharma America for relapsed or refractory myelofibrosis and other hematologic malignancies. Its differentiated mechanism of action, encouraging early clinical activity, combination potential, and regulatory designations are key factors supporting the future growth of the nuvisertib market.
Nuvisertib targets PIM1 kinase, which is associated with inflammatory signaling, malignant cell survival, cytokine production, and bone marrow fibrosis. In contrast to approved JAK inhibitors focused primarily on spleen and symptom control, nuvisertib has demonstrated potential effects on inflammatory cytokines, bone marrow fibrosis, hemoglobin levels, platelet counts, and spleen volume. Translational research also indicates that nuvisertib inhibits ACVR1, supporting a potential relationship between treatment, hepcidin modulation, and improved anemia outcomes.
Encouraging Nuvisertib Clinical Trial Results
Updated findings from the ongoing Phase I/II clinical trial, NCT04176198, presented at the European Hematology Association Congress in 2025 demonstrated encouraging activity in heavily pretreated patients with relapsed or refractory myelofibrosis. Among evaluable patients receiving nuvisertib monotherapy, 22.2% achieved at least a 25% reduction in spleen volume, while 44.4% achieved at least a 50% reduction in total symptom score. Bone marrow fibrosis improved in 42.9% of evaluable patients, with hemoglobin and platelet count improvements reported in 24% and 26.7%, respectively.
No dose-limiting toxicities were observed in the reported analysis, supporting continued dose optimization and clinical expansion. Commonly reported adverse events have included nausea, diarrhea, vomiting, fatigue, and reversible liver enzyme elevations. Nuvisertib remains investigational and has not received regulatory approval.
Nuvisertib and Momelotinib Combination Opportunity
The clinical development program has expanded to evaluate nuvisertib in combination with momelotinib, an approved JAK inhibitor for myelofibrosis in patients with anemia. Preliminary results presented at the EHA 2026 Congress indicated that the combination was generally well tolerated in a difficult-to-treat population. All participating patients had received prior JAK inhibitor therapy, and 41% had high molecular-risk mutations.
Among evaluable patients treated for 24 weeks, 60% achieved a reported response involving spleen size, symptom burden, or anemia. These preliminary findings suggest that combined PIM1, ACVR1, and JAK pathway inhibition may provide broader clinical activity than JAK inhibition alone. Confirmation in larger and later-stage studies could expand nuvisertib's addressable population and strengthen its commercial positioning within the myelofibrosis treatment market.
Regulatory and Development Milestones
Nuvisertib received US Food and Drug Administration Fast Track Designation for myelofibrosis in June 2025 and European Medicines Agency Orphan Drug Designation in July 2025. These milestones recognize the unmet need in myelofibrosis and may support more efficient regulatory interactions and development. In June 2026, Sumitomo Pharma America presented additional clinical and translational research at the EHA Congress in Stockholm, including the first preliminary clinical data for nuvisertib combined with momelotinib and research examining the mechanistic basis of hemoglobin improvement.
Nuvisertib Sales Forecast and Market Analysis to 2034
The report evaluates the drug's clinical, regulatory, and commercial potential across myelofibrosis, multiple myeloma, and triple-negative breast cancer. Geographic coverage includes the seven major markets: the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan. The analysis covers historical developments and forecast market performance from 2020 through 2034.
The nuvisertib market report includes sales forecasts, market size estimates, mechanism of action, dosage and administration, clinical trial activity, regulatory milestones, pricing considerations, reimbursement dynamics, patent information, potential generic entry, and projected launch timelines. It also assesses competitive positioning, anticipated peak sales, development barriers, commercial opportunities, and regional variations in uptake and cost.
Report Scope and Competitive Intelligence
- Current and forecast nuvisertib sales through 2034 across the seven major markets Clinical trial status, interventions, study timelines, and anticipated completion dates Market potential in myelofibrosis, multiple myeloma, and triple-negative breast cancer Nuvisertib pricing, reimbursement, cost estimates, and geographic variations Patent landscape, exclusivity considerations, and potential generic competition Pipeline analysis covering marketed products and late-stage emerging therapies SWOT analysis and expert perspectives on nuvisertib's competitive position Commercial partnerships, licensing agreements, mergers, and acquisition activity Regulatory milestones, expected launch timelines, and market-access considerations
Nuvisertib Market Outlook
Nuvisertib's market potential will depend on the strength and durability of future efficacy data, long-term safety, successful dose selection, regulatory progress, pricing, reimbursement, and competition from existing and emerging myelofibrosis therapies. Its non-JAK mechanism, potential disease-modifying activity, anemia-related findings, and compatibility with momelotinib may provide meaningful clinical differentiation.
The report supports pharmaceutical companies, investors, healthcare stakeholders, and portfolio strategy teams by providing a comprehensive assessment of nuvisertib sales forecasts, clinical differentiation, competitive threats, and commercial opportunities through 2034. As clinical development advances, additional evidence from larger studies will be essential to determine nuvisertib's role in myelofibrosis and its potential expansion into other oncology indications.
Key Topics Covered
1. Report Introduction
2. Nuvisertib Overview in potential indication like Myelofibrosis, Multiple myeloma, and Triple negative breast cancer
2.1. Product Detail
2.2. Nuvisertib Clinical Development
2.2.1. Nuvisertib Clinical studies
2.2.2. Nuvisertib Clinical trials information
2.2.3. Safety and efficacy
2.3. Other Developmental Activities
2.4. Product Profile
3. Nuvisertib Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Nuvisertib Therapies)
5. Nuvisertib Market Assessment
5.1. Nuvisertib Market Outlook in potential indications
5.2. 7MM Analysis
5.2.1. Nuvisertib Market Size in the 7MM for potential indications
5.3. Country-wise Market Analysis
5.3.1. Nuvisertib Market Size in the United States for potential indications
5.3.2. Nuvisertib Market Size in Germany for potential indications
5.3.3. Nuvisertib Market Size in France for potential indications
5.3.4. Nuvisertib Market Size in Italy for potential indications
5.3.5. Nuvisertib Market Size in Spain for potential indications
5.3.6. Nuvisertib Market Size in the United Kingdom for potential indications
5.3.7. Nuvisertib Market Size in Japan for potential indications
6. Nuvisertib SWOT Analysis
7. Analysts' Views
8. Appendix
8.1. Bibliography
8.2. Report Methodology
List of Tables
Table 1: Nuvisertib, Clinical Trial Description, 2023
Table 2: Nuvisertib, General Description
Table 3: Competitive Landscape (Marketed Therapies)
Table 4: Competitive Landscape (Emerging Therapies)
Table 5: Nuvisertib's pricing and cost Assumptions
Table 6: Nuvisertib's Sales Analysis in the 7MM, in USD million (2020-2034)
Table 7: Nuvisertib Market Size in the US, in USD million (2020-2034)
Table 8: Nuvisertib Market Size in Germany, in USD million (2020-2034)
Table 9: Nuvisertib Market Size in France, in USD million (2020-2034)
Table 10: Nuvisertib Market Size in Italy, in USD million (2020-2034)
Table 11: Nuvisertib Market Size in Spain, in USD million (2020-2034)
Table 12: Nuvisertib Market Size in the UK, in USD million (2020-2034)
Table 13: Nuvisertib Market Size in Japan, in USD million (2020-2034)
List of Figures
Figure 1: Nuvisertib's Sales Analysis in the 7MM, USD million (2020-2034)
Figure 2: Nuvisertib Market Size in the United States, USD million (2020-2034)
Figure 3: Nuvisertib Market Size in Germany, USD million (2020-2034)
Figure 4: Nuvisertib Market Size in France, USD million (2020-2034)
Figure 5: Nuvisertib Market Size in Italy, USD million (2020-2034)
Figure 6: Nuvisertib Market Size in Spain, USD million (2020-2034)
Figure 7: Nuvisertib Market Size in the United Kingdom, USD million (2020-2034)
Figure 8: Nuvisertib Market Size in Japan, USD million (2020-2034)
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment